Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
TEVETEN HCT 600mg/25mg |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Eprosartan (as mesylate) 600mg, hydrochlorothiazide 25mg; tabs. |
| Also |
|
• TEVETEN HCT 600mg/12.5mg
|
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Not for initial therapy. May be substituted for titrated components. One Teveten HCT 600mg/12.5mg tab once daily; after 2–3 weeks may increase to one Teveten HCT 600mg/25mg tab once daily. May add eprosartan 300mg once daily in the PM if additional BP control is needed at trough. |
| Contraindications |
|
Anuria. Sulfonamide allergy. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before starting, or monitor closely. Renal or hepatic dysfunction. Renal artery stenosis. Severe CHF. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Monitor electrolytes. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, or K+ containing salt substitutes. ACTH, corticosteroids, amphotericin B increase hypokalemia risk. Orthostatic hypotension potentiated by alcohol, CNS depressants. Antagonized by NSAIDs. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May interfere with parathyroid tests. May antagonize norepinephrine. |
| Adverse Reactions |
|
Dizziness, headache, back pain, fatigue, orthostatic hypotension, electrolyte disturbances, rash, adverse lipid values, rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
